Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
The Singaporean company has filed for a Hong Kong IPO, hoping to wow investors with its product that can screen for gastric cancer using blood tests Key Takeaways: Mirex’s blood-based…
RELATED ARTICLES
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
